Core Viewpoint - Aipeng Medical's stock has experienced significant fluctuations, with a year-to-date increase of 66.92% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 19, Aipeng Medical's stock price was 29.32 CNY per share, with a market capitalization of 3.696 billion CNY [1] - The stock has seen a decline of 5.08% over the last five trading days and 13.92% over the last twenty trading days [2] - Year-to-date, the stock has been on the龙虎榜 (top trading list) six times, with the most recent net buy of 11.9243 million CNY on August 8 [2] Group 2: Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 159 million CNY, a year-on-year decrease of 11.31%, and a net profit of -19.3791 million CNY, a decrease of 317.90% [2] - Cumulative cash dividends since the A-share listing amount to 113 million CNY, with 16.3862 million CNY distributed over the last three years [3] Group 3: Company Overview - Aipeng Medical, established on October 30, 2001, specializes in the development, production, and sales of medical devices in pain management and nasal care [2] - The company's revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [2] - As of June 30, 2025, the number of shareholders increased by 57.18% to 32,400, while the average circulating shares per person decreased by 36.33% to 2,711 shares [2]

Company Overview - Aipeng Medical experienced a decline of 5.03% on September 18, with a stock price of 29.65 yuan per share, a trading volume of 230 million yuan, a turnover rate of 8.57%, and a total market capitalization of 3.737 billion yuan [1] Business Operations - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, is located in the Jiangsu Province. The company specializes in the research, development, production, and sales of medical devices in the fields of pain management and nasal care [1] - The revenue composition of Aipeng Medical includes: 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [1] Fund Holdings - According to data, Beixin Ruifeng Fund has one fund heavily invested in Aipeng Medical. The Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056) held 120,000 shares, accounting for 4.43% of the fund's net value, ranking as the tenth largest holding [2] - The fund has reported a floating loss of approximately 188,400 yuan as of the latest data [2] Fund Performance - The Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056) was established on March 27, 2015, with a latest scale of 89.3779 million yuan. Year-to-date, it has achieved a return of 35.19%, ranking 2286 out of 8172 in its category. Over the past year, it has returned 70.92%, ranking 1705 out of 7980, and since inception, it has returned 28.7% [2]

Core Viewpoint - Aipeng Medical's stock price has shown significant volatility, with a year-to-date increase of 77.97% but a recent decline in the last 20 days by 7.71% [2] Group 1: Stock Performance - On September 17, Aipeng Medical's stock fell by 2.04%, trading at 31.26 CNY per share with a total transaction volume of 1.49 billion CNY and a market capitalization of 39.40 billion CNY [1] - The stock has experienced a 3.61% increase over the last five trading days and a 5.50% increase over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 1.59 billion CNY, a year-on-year decrease of 11.31%, and a net profit attributable to shareholders of -19.38 million CNY, a decrease of 317.90% [2] - Cumulative cash dividends since the company's A-share listing amount to 113 million CNY, with 16.39 million CNY distributed over the past three years [3] Group 3: Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 57.18% to 32,400, while the average circulating shares per person decreased by 36.33% to 2,711 shares [2] - Aipeng Medical has appeared on the trading leaderboard six times this year, with the most recent instance on August 8, where net purchases amounted to 11.92 million CNY [2]

Group 1 - The company emphasizes the importance of cash flow and accounts receivable management, implementing measures to improve customer credit management and accelerate payment collection [1] - The company focuses on performance assessment and lean management to enhance marketing management and improve the return on sales investment [1] - The company is exploring new growth opportunities through the clinical application of innovative business in the brain-computer interface field [1]

Group 1 - The core viewpoint of the article highlights that the company Aipeng Medical is currently in the design and development phase of its anesthesia puncture robot project, with plans to disclose updates based on research and clinical validation progress [1] - The company has successfully obtained three registration certificates for its next-generation ADM series anesthesia depth monitoring devices, which have been launched in over 20 provinces and have started generating sales [1] - The implementation of the "Guidelines for the Review of Imported Products in Government Procurement" (2021 version) by the Ministry of Finance and the Ministry of Industry and Information Technology mandates that the procurement ratio for domestic products of "electroencephalogram anesthesia depth monitoring devices" should not be less than 50%, which will further promote the development of domestic anesthesia depth monitoring devices and create opportunities for domestic substitution [1]

Group 1 - The core viewpoint of the article is that Aipeng Medical's anesthesia puncture robot project is still in the design and development stage, with disclosures to be made based on R&D progress and clinical validation [1] - The new generation ADM series anesthesia depth monitor has obtained three registration certificates and has been listed in over 20 provinces, generating sales [1] - The implementation of the "Guidelines for the Review of Imported Products in Government Procurement" (2021 version) by the Ministry of Finance and the Ministry of Industry and Information Technology mandates that the procurement ratio of domestic products for "electroencephalogram anesthesia depth monitors" should not be less than 50%, which will further promote the development of domestic anesthesia depth monitors and create opportunities for domestic substitution [1]

Company Overview - Aipeng Medical focuses on medical devices, particularly in pain management and upper airway management, while also exploring brain-computer interface innovations [4] - The company has a strategic partnership with Ruishen'an Medical, a leading player in the domestic neuroregulation field [4] ADHD Product Development - Recently, the company received two Class II medical device registration certificates for its "Multimodal ADHD Behavioral Training System," which includes both hospital and home versions [5][6] - The system utilizes AI to analyze EEG signals from the frontal lobe, providing a comprehensive training solution that integrates medication and behavioral management [6] Treatment Costs and Collaboration - The treatment cost for ADHD patients ranges from ¥10,000 to ¥25,000, depending on the severity of the condition [7] - The collaboration with Fudan University Children's Hospital has just begun, and the treatment process is expected to be lengthy due to the chronic nature of ADHD [7] Training Efficacy and Duration - Effective training typically requires 3 to 6 months, with higher frequency leading to better outcomes [8] - Behavioral therapy is highlighted as a viable method for leveraging neuroplasticity in ADHD treatment, contrasting with the potential side effects of stimulant medications [8] Market Challenges and Opportunities - The pain management business is currently experiencing a transitional phase due to centralized procurement policies, leading to a decrease in sales compared to the previous year [13] - The nasal airway management segment has faced challenges due to increased competition and a decline in retail performance, prompting the company to explore instant retail opportunities [14] Future Directions - The company plans to optimize retail and clinical sales strategies to enhance channel efficiency and adapt to changing consumer habits [14] - There is a focus on expanding partnerships with training institutions to disseminate the behavioral training system and course content [9]

北信瑞丰健康生活主题灵活配置（001056）基金经理为庞文杰。 从基金十大重仓股角度 数据显示，北信瑞丰基金旗下1只基金重仓爱朋医疗。北信瑞丰健康生活主题灵活配置（001056）二季 度持有股数12万股，占基金净值比例为4.43%，位居第十大重仓股。根据测算，今日浮亏损失约19.92万 元。 北信瑞丰健康生活主题灵活配置（001056）成立日期2015年3月27日，最新规模8937.79万。今年以来收 益38.97%，同类排名1228/8179；近一年收益76.4%，同类排名927/7984；成立以来收益32.3%。 9月9日，爱朋医疗跌5.07%，截至发稿，报31.05元/股，成交2.22亿元，换手率7.96%，总市值39.14亿 元。 资料显示，江苏爱朋医疗科技股份有限公司位于江苏省如东县经济开发区永通大道东侧，成立日期2001 年10月30日，上市日期2018年12月13日，公司主营业务涉及疼痛管理及鼻腔护理领域用医疗器械产品研 发、生产及销售。主营业务收入构成为：疼痛管理产品59.73%，鼻腔及上气道产品29.40%，其他 10.87%。 截至发稿，庞文杰累计任职时间5年102天，现任基金资产总规模1 ...

Core Viewpoint - Aipeng Medical (300753) announced that its subsidiary, Shenzhen Pengrui Brain Science Technology Co., Ltd., has recently obtained a medical device registration certificate [1] Company Summary - Aipeng Medical's subsidiary has achieved a significant milestone by securing a medical device registration certificate, which may enhance its market position and product offerings in the healthcare sector [1]

Group 1 - The company, Aipeng Medical (300753.SZ), announced that its subsidiary, Shenzhen Pengrui Brain Science Technology Co., Ltd., has recently obtained the Medical Device Registration Certificate issued by the Guangdong Provincial Drug Administration [1] - The registered products include a portable electroencephalogram (EEG) machine and a portable EEG collector [1]